Physician profile
Thomas E Rohrer
NPI 1053384693
$9,020.54
in general payments reported to CMS, 2019-2025
30 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what 83% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,037 · 2020: $688 · 2021: $1,230 · 2022: $1,201 · 2023: $1,468 · 2024: $1,871 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,863.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,719.97 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $770.18 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $746.56 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Lilly USA, LLC | $613.85 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $554.19 | 2019-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $533.67 | 2020-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $518.74 | 2019-2025 | |
| Galderma Laboratories, L.P. | $489.28 | 2019-2025 | Nemluvio |
| Incyte Corporation | $472.84 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $465.83 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $354.18 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $232.59 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $199.91 | 2019-2024 | |
| Genentech USA, INC. | $186.59 | 2019-2024 | Xolair |
| Revance Therapeutics, INC. | $152.85 | 2024-2025 | Daxxify |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $112.79 | 2019-2021 | |
| Pfizer INC. | $112.71 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.50 | 2022-2023 | Spevigo |
| Allergan, INC. | $105.52 | 2022 | |
| Organon LLC | $89.06 | 2025 | Vtama |
| Celgene Corporation | $86.66 | 2019 | |
| Arcutis Biotherapeutics, INC. | $85.43 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $76.24 | 2022-2024 | Vtama |
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Mission Pharmacal Company | $45.60 | 2019 | |
| Mylan Pharmaceuticals INC. | $33.25 | 2019 | |
| Botanix Sb INC | $26.26 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $23.10 | 2019 | |
| Aclaris Therapeutics, INC. | $22.14 | 2019 | |
| Osiris Therapeutics INC. | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rohrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.